# DESCRIPTION

## FIELD OF THE INVENTION

- relate to monomeric fusion proteins

## BACKGROUND

- introduce TSLP
- describe TSLP function
- discuss TSLP receptors
- explain TSLP signaling
- describe TSLP-related diseases
- discuss TSLP as therapeutic target
- summarize limitations of current TSLP blockers
- motivate need for alternative TSLP inhibitors
- discuss prior art
- highlight unmet need for effective TSLP treatment

## SUMMARY

- introduce TSLP-trap
- describe TSLP-trap composition
- summarize TSLP-trap advantages
- describe embodiments of TSLP-trap
- outline uses of TSLP-trap

## DETAILED DESCRIPTION

- introduce patent description
- define scope of invention
- explain drawings and reference signs
- define terms and definitions
- motivate fusion protein
- define monomeric fusion protein
- define protein and polypeptide
- explain extracellular part of protein
- define linker
- define nucleic acid
- explain treatment and treating
- define cancer
- introduce first aspect of invention
- describe monomeric fusion protein
- explain functional extracellular parts
- describe TSLPR and IL-7Ralpha
- explain functional assays
- describe SEQ ID NO: 1 and SEQ ID NO: 2
- explain mammal and homologues
- describe fusion protein composition
- explain secretion signal and fusion flexibility
- describe fusion protein structure
- specify linker types
- detail peptide-based linker
- describe non-peptide linker
- specify PEG-based linker
- describe linker conjugation
- introduce protein tag
- describe monomeric fusion protein
- specify further moieties
- describe binding affinity
- specify KD values
- describe derivatives
- define inhibition
- specify IC50 values
- describe nucleic acid molecules
- introduce recombinant expression vectors
- describe host cells
- specify host cell types
- describe gene expression
- specify expression and purification conditions
- describe protein production
- specify purification techniques
- introduce medical use
- specify inflammatory diseases
- specify cancer types
- specify fibrosis types
- describe treatment methods
- specify administration routes
- introduce pharmaceutical composition
- specify carriers
- describe additives
- specify treatment methods
- describe co-administration

## EXAMPLES

### Materials and Methods to the Examples

- design TSLP-traps
- describe human TSLP-trap1
- describe human TSLP-trap2
- include secretion signal
- include His-tag
- clone cDNA fragments
- generate stable cell lines
- induce expression
- harvest conditioned medium
- purify recombinant proteins
- produce neutralizing anti-TSLP antibody
- produce Fab-fragment
- perform biolayer interferometry
- produce biotinylated TSLP
- describe TSLP induced STATS reporter assay
- describe inhibition in TSLP induced STATS reporter assay
- describe mouse strains
- maintain mice in animal facility
- approve experiments by animal ethical committees
- describe experimental conditions

### Example 1

- generate TSLP-traps
- describe TSLP-trap1 and TSLP-trap2

### Example 2

- characterize interaction between TSLP and TSLPR ectodomain
- characterize interaction between TSLP and TSLP-trap1

### Example 3

- evaluate inhibitory potency of TSLP-traps
- compare to TSLPR and IL-7Ralpha ectodomain
- compare to neutralizing anti-TSLP antibody

### Example 4

- describe mouse model of HDM-induced allergic airway inflammation
- evaluate effect of TSLP-trap in mouse model
- assess features of allergic airway inflammation

### Example 5

- describe atopic dermatitis mouse model
- evaluate effect of TSLP-trap in atopic dermatitis mouse model
- assess atopic dermatitis-like inflammation

